(2M6) Medtronic - Ratings and Ratios
Exchange: XETRA • Country: Ireland • Currency: EUR • Type: Common Stock • ISIN: IE00BTN1Y115
2M6: Devices, Pacemakers, Valves, Implants, Instruments, Systems
Medtronic PLC, traded as 2M6 on the XETRA exchange, is a global leader in medical technology, specializing in device-based therapies that address a wide range of chronic and acute health conditions. With a market capitalization of approximately €111.9 billion, the company operates across four core segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. This diversification not only reduces dependency on any single market but also positions Medtronic as a one-stop solution provider in healthcare.
The Cardiovascular Portfolio is Medtronics largest contributor, offering a comprehensive suite of products for heart-related conditions. This includes implantable pacemakers, defibrillators, and cardiac resynchronization devices, which are critical for managing arrhythmias and heart failure. The segment also covers structural heart solutions, such as transcatheter aortic valves, which have seen rapid adoption due to their minimally invasive nature. Additionally, Medtronic provides tools for cardiac ablation and remote patient monitoring, showcasing its commitment to both treatment and prevention.
The Neuroscience Portfolio focuses on conditions affecting the brain, spine, and nervous system. It includes spinal cord stimulation systems for chronic pain, deep brain stimulation for movement disorders like Parkinsons, and implantable drug delivery systems for severe pain and spasticity. This segment also offers surgical instruments for neurosurgeons and orthopedic specialists, along with diagnostic tools for conditions like hydrocephalus. The diversity of this portfolio underscores Medtronics ability to address complex neurological disorders with precision.
The Medical Surgical Portfolio is geared toward operating rooms and surgical procedures. It features advanced stapling devices, vessel-sealing technologies, and robotic-assisted surgery products. A notable highlight is the Hugo robotic-assisted surgery system, which competes in the fast-growing market of minimally invasive robotics. This segment also includes diagnostic and monitoring tools, such as AI-powered surgical video platforms, which enhance surgical precision and patient
Additional Sources for 2M6 Stock
2M6 Stock Overview
| Market Cap in USD | 121,691m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
2M6 Stock Ratings
| Growth 5y | 17.0% |
| Fundamental | 37.5% |
| Dividend | 62.4% |
| Rel. Strength Industry | 10.3 |
| Analysts | - |
| Fair Price Momentum | 85.07 EUR |
| Fair Price DCF | 98.50 EUR |
2M6 Dividends
| Dividend Yield 12m | 3.33% |
| Yield on Cost 5y | 4.24% |
| Annual Growth 5y | 4.12% |
| Payout Consistency | 91.7% |
2M6 Growth Ratios
| Growth Correlation 3m | 72.1% |
| Growth Correlation 12m | 79.9% |
| Growth Correlation 5y | -31.9% |
| CAGR 5y | 5.62% |
| CAGR/Max DD 5y | 0.14 |
| Sharpe Ratio 12m | 0.23 |
| Alpha | 7.77 |
| Beta | 0.13 |
| Volatility | 23.36% |
| Current Volume | 1.5k |
| Average Volume 20d | 1.3k |
As of March 13, 2025, the stock is trading at EUR 83.64 with a total of 1,543 shares traded.
Over the past week, the price has changed by -4.48%, over one month by -4.69%, over three months by +6.38% and over the past year by +10.16%.
Partly, yes. Based on ValueRay Fundamental Analyses, Medtronic (XETRA:2M6) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.54 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of 2M6 as of March 2025 is 85.07. This means that 2M6 is currently overvalued and has a potential downside of 1.71%.
Medtronic has no consensus analysts rating.
According to ValueRays Forecast Model, 2M6 Medtronic will be worth about 91.9 in March 2026. The stock is currently trading at 83.64. This means that the stock has a potential upside of +9.85%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 91.9 | 9.9% |